Mesoblast Ltd is a biotechnology company focused on developing and commercializing allogeneic cell-based therapies for inflammatory and cardiovascular diseases. Founded in 2004 and headquartered in Melbourne, Australia, the company leverages proprietary mesenchymal lineage cell technologies to address conditions with high unmet medical need. Mesoblast’s platform centers on mesenchymal precursor cells (MPCs) and mesenchymal stem cells (MSCs), which are manufactured in a scalable, off-the-shelf form to deliver anti-inflammatory and tissue-regenerative effects.
The company’s lead product, remestemcel-L, is in advanced clinical trials for pediatric steroid-refractory acute graft-versus-host disease (aGvHD) and is under regulatory review in multiple regions. In Japan, Mesoblast markets TEMCELL HS, an autologous MSC therapy approved for aGvHD, through its partner JCR Pharmaceuticals. In Asia Pacific, the company has secured approvals for REVASCOR, an MPC-based treatment for chronic heart failure, in Australia and New Zealand. Mesoblast’s pipeline also includes candidates targeting chronic low back pain with disc degeneration, inflammatory bowel disease, and acute respiratory distress syndrome (ARDS).
With commercial and clinical operations spanning North America, Europe, Asia Pacific and Latin America, Mesoblast has forged strategic partnerships to accelerate development and commercialization. Collaborations with Tasly in China aim to expand the reach of mesenchymal therapies, while agreements with Teva Pharmaceuticals and other specialty biopharma firms support ongoing research and regulatory filings. The company’s manufacturing network includes facilities in Australia and the United States, ensuring consistent production quality for global clinical studies and supply.
Under the leadership of co-founder and CEO Dr. Silviu Itescu, Mesoblast has advanced from early-stage research to late-stage clinical development across multiple indications. The company’s board and management team bring expertise in regenerative medicine, cell and gene therapy, and pharmaceutical commercialization. Mesoblast continues to pursue additional regulatory approvals and strategic collaborations to extend its pipeline and deliver novel cell therapies to patients worldwide.
AI Generated. May Contain Errors.
Free MEOBF Stock Alerts